Which manufacturer is Ruibosili/Kaillon?

Ribociclib/Calilon (Ribociclib) is a new targeted anti-cancer drug developed and produced by the Swiss pharmaceutical company Novartis. Novartis has leading R&D capabilities and rich experience in oncology drug development in the global pharmaceutical industry. Its R&D team focuses on the research of CDK4/6 inhibitors. Riboxiclib is one of its important achievements in the treatment of breast cancer. During the drug development process, Novartis has verified the efficacy and safety of Riboxiclib in patients with hormone receptor-positive, HER2-negative advanced breast cancer through global multi-center clinical trials. It has shown obvious disease control advantages especially when combined with endocrine therapy.

The launch of Riboxiclib not only fills the gap in the treatment of hormone receptor-positive breast cancer, but also provides patients around the world with the option of oral targeted therapy, reducing the adverse reactions associated with traditional chemotherapy while improving the quality of life of patients. Globally, Novartis is responsible for drug production, quality control and supply chain management, ensuring the accessibility and stable supply of drugs in various countries and regions. In the domestic market, the original drug Riboxil has been officially launched and is authorized for distribution by Novartis. Patients can obtain it through regular hospitals and pharmacies. It is worth noting that since the drug is a high-end anti-cancer drug, individualized assessment must be conducted under the guidance of a doctor before use, including liver function, electrocardiogram and blood picture monitoring to ensure drug safety.

In addition, in addition to drug research and development, Novartis also provides patient education and medication guidance services to help patients understand the drug's mechanism of action, precautions and adverse reaction management, and improve compliance and treatment effects. As one of Novartis' core anti-breast cancer products, Riboxiclib's global promotion strategy also emphasizes standardized medication use, scientific monitoring and patient care to ensure that every patient who meets the indications can receive a safe and effective treatment experience.

Reference materials:https://us.kisqali.com/